Over 50% of human breast cancer cases show amplification and/or overexpression of c-myc oncogene and some c-Myc regulated genes, like cyclin D1. However, while some studies show an association of c-myc expression or amplification with tumor aggressiveness of this disease, other studies report the opposite. This controversy may be related to the fact that c-Myc can commit a cell to either proliferation or apoptosis: while c-Myc-promoted cell proliferation makes the tumor more aggressive, c-Myc-initiated apoptosis should result in a favorable outcome. The decision on whether c-Myc should direct a cell to proliferate or to die is made under a strong influence of transforming growth factor alpha (TGFalpha). Our previous studies have shown that mammary tumors developed from MMTV-c-myc transgenic mice further progress to some focal lesions with more aggressive features. The appearance of these 'tumor-within-a-tumor"""""""" foci makes this transgenic mouse the first animal model of mammary carcinogenesis that shows identifiable multiple-steps of tumor progression. Studies with MT-tgfalphaMMTV-c-myc dual transgenic mice show TGFalpha induces cyclin D1 as an intermediator to prevent c-Myc-initiated apoptosis, leading to an early development of a more aggressive tumor phenotype, compared to the c-myc transgenic tumor. In this project, we aim to use these transgenic animals to study whether c-Myc induces expression of e2f1 and cyclin A2 to mediate the cell proliferation and mammary tumor onset while it suppresses cyclin D1 to hamper further progression of the tumor and to initiate apoptosis. We will also explore whether TGFalpha promotes mammary carcinogenesis by inducing cyclin D1 as an intermediator to prevent c-Myc-initiated apoptosis. It will further be studied whether inhibition of both c-myc and cyclin D1 will result in a better therapeutic effect than inhibition of each gene alone on breast cancer. The long-term objective of the project is to use the information resulted from these proposed studies to direct the treatment of breast cancer patients with agents that inhibit expression of both c-myc and cyclin D1 for a better therapeutic outcome; candidate agents include modified anti-gene oligonucleotides (MAGON) and a new anticancer drug FR901228.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100864-03
Application #
6891587
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Perry, Mary Ellen
Project Start
2003-06-09
Project End
2008-03-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
3
Fiscal Year
2005
Total Cost
$333,706
Indirect Cost
Name
Wayne State University
Department
Pathology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Sun, Y; Cao, S; Yang, M et al. (2013) Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4. Oncogene 32:1794-810
Yang, Min; Wu, Jack; Wu, Si-Hung et al. (2012) Splicing of mouse p53 pre-mRNA does not always follow the ""first come, first served"" principle and may be influenced by cisplatin treatment and serum starvation. Mol Biol Rep 39:9247-56
Wang, Chenguang; Lisanti, Michael P; Liao, D Joshua (2011) Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 10:57-67
Wang, Chenguang; Tai, Yanhong; Lisanti, Michael P et al. (2011) c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther 11:615-26
Sun, Yuan; Wu, Jack; Wu, Si-hung et al. (2009) Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat 118:185-96
Wu, Jack; Wu, Si-hung; Bollig, Aliccia et al. (2009) Identification of the cyclin D1b mRNA variant in mouse. Mol Biol Rep 36:953-7
Thakur, Archana; Sun, Yuan; Bollig, Aliccia et al. (2008) Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin Cancer Res 14:4427-36
Thakur, Archana; Rahman, Km Wahidur; Wu, Jack et al. (2007) Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol Cancer Res 5:171-81
Liao, D Joshua; Thakur, Archana; Wu, Jack et al. (2007) Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog 13:93-158
Wang, Yong; Thakur, Archana; Sun, Yuan et al. (2007) Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Cancer Res 67:3698-707

Showing the most recent 10 out of 16 publications